Integra LifeSciences Holdings Gestion

Gestion contrôle des critères 3/4

Le PDG Integra LifeSciences Holdings est Jan De Witte, nommé en Dec2021, a un mandat de 2.92 ans. La rémunération annuelle totale est $ 6.39M, composée du salaire de 13.7% et des bonus 86.3%, y compris les actions et options de la société. détient directement 0.031% des actions de la société, d'une valeur de € 527.99K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.6 ans et 11.5 ans.

Informations clés

Jan De Witte

Directeur général

US$6.4m

Rémunération totale

Pourcentage du salaire du PDG	13.7%
Durée du mandat du directeur général	2.9yrs
Propriété du PDG	0.03%
Durée moyenne d'occupation des postes de direction	3.6yrs
Durée moyenne du mandat des membres du conseil d'administration	11.5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Jan De Witte a-t-elle évolué par rapport aux bénéfices de Integra LifeSciences Holdings?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-US$7m
Jun 30 2024	n/a	n/a	US$24m
Mar 31 2024	n/a	n/a	US$40m
Dec 31 2023	US$6m	US$875k	US$68m
Sep 30 2023	n/a	n/a	US$101m
Jun 30 2023	n/a	n/a	US$131m
Mar 31 2023	n/a	n/a	US$172m
Dec 31 2022	US$9m	US$850k	US$181m
Sep 30 2022	n/a	n/a	US$173m
Jun 30 2022	n/a	n/a	US$166m
Mar 31 2022	n/a	n/a	US$157m
Dec 31 2021	US$899k	US$59k	US$169m

Rémunération vs marché: La rémunération totale de Jan ($USD 6.39M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché German ($USD 1.63M ).

Rémunération et revenus: La rémunération de Jan a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Jan De Witte (60 yo)

2.9yrs

Titularisation

US$6,388,756

Compensation

Mr. Jan De Witte has been President, Chief Executive Officer & Director of Integra LifeSciences Holdings Corporation since December 1, 2021. He had been the Chief Executive Officer at Barco NV since Septem...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Stuart Essig	Executive Chairman	26.9yrs	US$422.52k	2.27% € 38.7m
Jan De Witte	President	2.9yrs	US$6.39m	0.031% € 528.0k
Lea Knight	Executive VP & CFO	1.4yrs	US$1.67m	0.054% € 926.3k
Jeffrey Mosebrook	Senior VP of Finance & Principal Accounting Officer	7.1yrs	US$1.25m	0.047% € 797.1k
Eric Schwartz	Executive VP	6yrs	US$1.62m	0.082% € 1.4m
Robert Davis	Executive VP & President of Tissue Technologies	11.9yrs	US$1.42m	0.084% € 1.4m
Michael McBreen	Executive VP & President of Codman Specialty Surgical	4.5yrs	US$2.83m	0.075% € 1.3m
Stephen Leonard	Corporate VP of Global Operations & Supply Chain	4.3yrs	pas de données	pas de données
Laurene Isip	Vice President of Global Corporate Communications & Public Relations	no data	pas de données	pas de données
Ruth Fleming	Vice President of Global Marketing	no data	pas de données	pas de données
Chantal Veillon-Berteloot	Executive VP & Chief Human Resources Officer	1.8yrs	pas de données	0.032% € 538.4k
Mark Jesser	Corporate VP & Chief Digital Officer	2.8yrs	pas de données	pas de données

3.6yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe de direction de IL3 est considérée comme expérimentée (ancienneté moyenne 3.6 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Stuart Essig	Executive Chairman	26.9yrs	US$422.52k	2.27% € 38.7m
Jan De Witte	President	2.9yrs	US$6.39m	0.031% € 528.0k
Raymond Murphy	Independent Director	15.6yrs	US$297.54k	0.11% € 1.8m
Christian Schade	Independent Director	18.8yrs	US$293.28k	0.082% € 1.4m
Barbara Hill	Independent Presiding Director	11.5yrs	US$342.54k	0.18% € 3.0m
Keith N. Bradley	Independent Director	32.8yrs	US$306.31k	0.091% € 1.5m
Jeffrey Graves	Independent Director	less than a year	US$90.68k	0.016% € 275.9k
Shaundra Clay	Independent Director	3.6yrs	US$260.04k	0.028% € 484.2k
Renee Lo	Independent Director	2.3yrs	US$297.54k	0.021% € 356.7k

11.5yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la IL3 est chevronné et expérimenté ( 11.5 années d'ancienneté moyenne).

Integra LifeSciences Holdings Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Independent Presiding Director recently bought €917k worth of stock

Integra LifeSciences Holdings Corporation, Annual General Meeting, May 09, 2024

Integra LifeSciences Holdings Corporation Announces Board Changes

Integra Lifesciences Holdings Corporation Appoints Lea Daniels Knight as Executive Vice President, Effective June 28, 2023

President recently bought €279k worth of stock

Insider recently sold €95k worth of stock

Recent updates

Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Updates Earnings Guidance for the Full Year of 2024

Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.24 profit in 3Q 2023)

Investor sentiment deteriorates as stock falls 21%

Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.052 profit in 2Q 2023)

Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the Third Quarter and Updates Earnings Guidance for the Full Year of 2024

Integra LifeSciences Holdings Corporation to Report Q2, 2024 Results on Jul 29, 2024

Integra LifeSciences Holdings Corporation(NasdaqGS:IART) dropped from Russell 1000 Dynamic Index

Independent Presiding Director recently bought €917k worth of stock

Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Second Quarter and Full Year 2024

New minor risk - Share price stability

First quarter 2024 earnings released: US$0.042 loss per share (vs US$0.30 profit in 1Q 2023)

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.

Integra LifeSciences Holdings Corporation to Report Q1, 2024 Results on Apr 25, 2024

Integra LifeSciences Holdings Corporation, Annual General Meeting, May 09, 2024

Integra Lifesciences Launches Micromatrix Flex to Provide Convenient Access to Hard-To-Reach Areas in Complex Cases

Investor sentiment deteriorates as stock falls 19%

Integra LifeSciences Holdings Corporation Announces Board Changes

Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the First Quarter and for the Full Year 2024

Full year 2023 earnings released: EPS: US$0.84 (vs US$2.18 in FY 2022)

Integra LifeSciences Holdings Corporation to Report Q4, 2023 Results on Feb 28, 2024

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.

Third quarter 2023 earnings released: EPS: US$0.24 (vs US$0.60 in 3Q 2022)

Levi & Korsinsky Notifies Integra Lifesciences Holdings Corporation Investors of a Class Action Lawsuit and Upcoming Deadline

Integra LifeSciences Holdings Corporation to Report Q3, 2023 Results on Oct 25, 2023

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Integra Lifesciences Holdings Corporation

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Integra Lifesciences Holdings Corporation

New minor risk - Earnings quality

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) announces an Equity Buyback for $225 million worth of its shares.

Second quarter 2023 earnings released: EPS: US$0.052 (vs US$0.54 in 2Q 2022)

Integra LifeSciences Holdings Corporation to Report Q2, 2023 Results on Jul 27, 2023

Integra LifeSciences Holding Corporation Announces Complete Enrollment in DuraSorb Monofilament Mesh U.S. IDE Study

Integra Lifesciences Holdings Corporation Appoints Lea Daniels Knight as Executive Vice President, Effective June 28, 2023

President recently bought €279k worth of stock

Now 35% undervalued after recent price drop

Now 20% undervalued after recent price drop

First quarter 2023 earnings released: EPS: US$0.29 (vs US$0.39 in 1Q 2022)

Insider recently sold €95k worth of stock

Insider recently sold €203k worth of stock

Full year 2022 earnings released: EPS: US$2.16 (vs US$2.00 in FY 2021)

Now 20% undervalued

Integra LifeSciences Holdings Corporation Announces Executive Changes

Now 21% undervalued

Integra LifeSciences Holdings Corporation Provides Revenue Guidance for Fourth Quarter 2022 and Full-Year 2022

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) completed the acquisition of Surgical Innovation Associates, Inc.

Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire Surgical Innovation Associates, Inc. for $140 million.

Third quarter 2022 earnings released: EPS: US$0.60 (vs US$0.51 in 3Q 2021)

Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year

Integra LifeSciences Holdings Corporation to Report Q3, 2022 Results on Oct 26, 2022

Integra LifeSciences Holdings Corporation Appoints Harvinder Singh as Executive Vice President and President of Integra’s International Business

Integra LifeSciences Holdings Corporation Announces Resignation of Glenn Coleman as Chief Operating Officer, Effective October 3, 2022

Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO

Independent Director recently sold €439k worth of stock

An unknown buyer entered into a definitive agreement to acquire Non-core Traditional Wound Care Business of Integra LifeSciences Holdings Corporation (NasdaqGS:IART) for $28.8 million.

Second quarter 2022 earnings released: EPS: US$0.54 (vs US$0.41 in 2Q 2021)

Integra LifeSciences Holdings Corporation Revises Financial Guidance for the Third Quarter and Full Year 2022

Integra LifeSciences Holdings Corporation Appoints Renee Lo to its Board of Directors

Integra LifeSciences Holdings Corporation to Report Q2, 2022 Results on Jul 27, 2022

First quarter 2022 earnings released: EPS: US$0.39 (vs US$0.54 in 1Q 2021)

Integra LifeSciences Holdings Corporation, Annual General Meeting, May 13, 2022

Integra LifeSciences Holdings Corporation to Report Q1, 2022 Results on Apr 27, 2022

Insider recently sold €75k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the First Quarter and Full Year 2022

Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2021

Insider recently sold €214k worth of stock

Third quarter 2021 earnings released: EPS US$0.51 (vs US$0.38 in 3Q 2020)

Insider recently sold €242k worth of stock

Second quarter 2021 earnings released: EPS US$0.41 (vs US$0.004 loss in 2Q 2020)